Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
Year: 2009
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W88663011
